Tokyo, Sept. 16 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062910) titled 'An observational study of sarcopenia risk assessment and glycemic management in patients aged 65 years or older patients with type 2 diabetes' on Sept. 16.
Study Type:
Observational
Primary Sponsor:
Institute - Sumitomo Pharma Co., Ltd.
Condition:
Condition - Type 2 diabetes mellitus
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To prospectively examine glycemic management (HbA1c) over 48 weeks, as assessed by HbA1c, according to sarcopenia risk status using the finger-ring test in older patients with type 2 diabetes mellitus. In addition, the proportion and characteristics of patients at risk of sarcopenia will be investigated.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 65
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1) Aged 65 years or older at the time of consent
2) Diagnosed with type 2 diabetes mellitus by a physician
3) Prescribed diabetes medication
4) Understood the web-based explanation and provided voluntary informed consent to participate
Key exclusion criteria - None
Target Size - 1300
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 07 Month 14 Day
Date of IRB - 2026 Year 07 Month 14 Day
Anticipated trial start date - 2026 Year 09 Month 18 Day
Last follow-up date - 2027 Year 09 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072029
Disclaimer: Curated by HT Syndication.
